Finnish biotech start-up Nightingale is looking to pick up where Theranos left off, by revolutionising diagnostic medicine with its magnetic resonance biomarker test. So in order to get the level of certainty of one individual's condition, you need millions. The company has already raised $US1 million in a seed round led by the Australian venture capital firm Accel Partners, and it plans to launch clinical trials later this year. CEO Teemu Suna said that, unlike Theranos, Nightingale prefers to share its results and remain open to peer scrutiny, adding that its rival's downfall had put off investors in the sector.
Finnish biotech start-up Nightingale is looking to pick up where Theranos left off, by revolutionising diagnostic medicine with its magnetic resonance biomarker test. The company has already raised $US1 million in a seed round led by the Australian venture capital firm Accel Partners, and it plans to launch clinical trials later this year. CEO Teemu Suna said that, unlike Theranos, Nightingale prefers to share its results and remain open to peer scrutiny, adding that its rival's downfall had put off investors in the sector.